- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 309/04 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 309/04
Total number of patents in this class: 258
10-year publication summary
|
20
|
17
|
24
|
13
|
9
|
10
|
11
|
16
|
16
|
7
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| BASF SE | 20940 |
14 |
| Bristol-myers Squibb Company | 4880 |
9 |
| Merck Patent GmbH | 5815 |
9 |
| JNC Corporation | 1561 |
9 |
| JNC Petrochemical Corporation | 399 |
9 |
| Vitae Pharmaceuticals, Inc. | 96 |
8 |
| Boehringer Ingelheim International GmbH | 4642 |
5 |
| Syngenta Limited | 454 |
5 |
| Sumitomo Chemical Company, Limited | 9043 |
5 |
| Oryzon Genomics S.A. | 106 |
5 |
| The University of North Carolina at Chapel Hill | 2040 |
5 |
| AstraZeneca AB | 2892 |
4 |
| Abbvie Inc. | 1800 |
4 |
| Duke University | 3069 |
4 |
| Astellas Pharma Inc. | 1087 |
4 |
| Givaudan SA | 1889 |
4 |
| Janssen Pharmaceutica N.V. | 3394 |
3 |
| California Institute of Technology | 3977 |
3 |
| Galderma Research & Development | 404 |
3 |
| Symrise AG | 1727 |
3 |
| Other owners | 143 |